Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis. Dermatology Reports, [S. l.], v. 14, n. 3, 2022. DOI: 10.4081/dr.2022.9282. Disponível em: https://journals.pagepress.org/dr/article/view/9282. Acesso em: 4 aug. 2025.